TREAT (2009) — Trial Summary

TREAT (2009): Darbepoetin alfa did not reduce the risk of death, cardiovascular events, or renal events in patients with type 2 diabetes, CKD, and anemia, and was associated with an increased risk of stroke.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.